DDX41 Antibody (E-8): sc-166255

DDX41 Antibody (E-8) is a mouse monoclonal IgG2a antibody that detects DDX41 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DDX41 is a 622 amino acid protein encoded by the human gene DDX41 and is a member of the DEAD box helicase family, specifically the DDX41 subfamily. Anti-DDX41 antibody (E-8) plays a crucial role in studying post-transcriptional gene expression, particularly in pre-mRNA splicing, which is essential for the proper processing of RNA molecules before they are translated into proteins. The structure of DDX41 includes one CCHC-type zinc finger, one helicase ATP-binding domain, and one helicase C-terminal domain, which are vital for its function as a probable ATP-dependent RNA helicase. RNA helicases like DDX41 are highly conserved enzymes that harness energy from nucleoside triphosphate hydrolysis to alter RNA structures, thereby facilitating various biological processes involving RNA, including transcription, splicing, and translation. The ability of DDX41 to interact with other proteins involved in RNA metabolism underscores its importance in maintaining cellular function and gene regulation, making DDX41 (E-8) monoclonal antibody an invaluable tool for researchers studying RNA dynamics and gene expression pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DDX41 Antibody (E-8) References:

1. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.  |  Lewinsohn, M., et al. 2016. Blood. 127: 1017-23. PMID: 26712909
2. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia.  |  Chlon, TM., et al. 2021. Cell Stem Cell. 28: 1966-1981.e6. PMID: 34473945
3. R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability.  |  Mosler, T., et al. 2021. Nat Commun. 12: 7314. PMID: 34916496
4. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.  |  Duployez, N., et al. 2022. Blood. 140: 756-768. PMID: 35443031
5. Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies.  |  Weinreb, JT. and Bowman, TV. 2022. FEBS Lett. 596: 2736-2745. PMID: 36036093
6. DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells.  |  Shinriki, S., et al. 2022. Leukemia. 36: 2605-2620. PMID: 36229594
7. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.  |  Homan, CC., et al. 2023. Blood Adv. 7: 6092-6107. PMID: 37406166
8. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.  |  Bataller, A., et al. 2023. Am J Hematol. 98: 1780-1790. PMID: 37665752
9. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.  |  Maierhofer, A., et al. 2023. Blood Adv. 7: 7346-7357. PMID: 37874914
10. Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation.  |  Hwang, WC., et al. 2024. Leukemia. 38: 1353-1364. PMID: 38514771

The preferred DDX41 antibody is DDX41 Antibody (C-3): sc-166225.